XML 79 R16.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Product Milestone Payments and Royalty Agreements | 12 Months Ended
--- | ---
Dec. 31, 2013
Text Block [Abstract] |
Product Milestone Payments and Royalty Agreements | 10. Product Milestone Payments and Royalty Agreements In connection with an Asset Purchase Agreement with Tolerance Therapeutics, Inc. (“Tolerance”) entered into during June 2005, the Company may be required to issue Tolerance additional consideration as follows: (i) $10,950,000 if certain milestones are met, including the initiation of Phase 3 trials and filing of various regulatory product license applications; (ii) 36,135 shares of common stock; and (iii) royalty payments between 1.75% and 4.0% of net sales of products acquired from or patented by Tolerance or other product fees earned by the Company. Any additional consideration required to be paid under the Asset Purchase Agreement will be recorded as research and development expense when incurred. No payments related to the additional consideration have occurred during the three years ended December 31, 2013. Additionally, certain agreements require the Company to pay royalties. Currently, the Company is not obligated to pay royalties, as no revenue from product sales is being generated by the Company.

X
- Definition Royalty agreement disclosure. + References No definition available. + Details
Name: | mgnx_RoyaltyAgreementDisclosureTextBlock
Namespace Prefix: | mgnx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration